Preživljavanje hirurški lečenih bolesnika sa odmaklim karcinomom larinksa u Srbiji

  • Jovica Milovanović Clinical Center of Serbia, Clinic for Otorhinolaryngology and Maxillofacial Surgery,‚Belgrade, Serbia
  • Ana Jotić Clinical Center of Serbia, Clinic for Otorhinolaryngology and Maxillofacial Surgery, Belgrade, Serbia
  • Ljiljana Tešić Vidović General Hospital Loznica, Loznica, Serbia
  • Vojko Djukić Clinical Center of Serbia, Clinic for Otorhinolaryngology and Maxillofacial Surgery, Belgrade, Serbia
  • Aleksandar Trivić Clinical Center of Serbia, Clinic for Otorhinolaryngology and Maxillofacial Surgery, Belgrade, Serbia
  • Sanja Krejović Trivić Clinical Center of Serbia, Clinic for Otorhinolaryngology and Maxillofacial Surgery, Belgrade, Serbia
  • Zorana Radin General Hospital “Dr Djordje Jovanović”, Zrenjanin, Serbia
  • Katarina Savić Vujović University of Belgrade, Faculty of Medicine, Department of Pharmacology, Clinical Pharmacology and Toxicology, Belgrade, Serbia
  • Andjela Milovanović Clinical Center of Serbia, Clinic for Physical Medicine and Rehabilitation, Belgrade, Serbia
  • Bojan Banko Clinical Center of Serbia, Center for Radiology and Magnetic Resonance Imaging, Belgrade, Serbia
  • Vera Artiko Clinical Center of Serbia, Institute for Nuclear Medicine, Belgrade, Serbia
DOI: https://doi.org/10.2298/VSP171226138M
Ključne reči: larinks, neoplazme, postoperativni period, preživljavanje, faktori rizika, neoplazme, određivanje stadijuma

Sažetak


Apstrakt

 

Uvod/Cilj. Karcinomi larinksa čine 1%–3% svih maligniteta glave i vrata. Terapijski rezultati i preživljavanje umnogome zavise od stadijuma bolesti. Cilj rada bio je da se ispita preživljavanje bolesnika, hirurški lečenih od odmaklih karcinoma larinksa, u zavisnoti od starosti, pola, uobičajenih faktora rizika (pušenje, konzumiranje alkohola), primarne lokalizacije tumora, patohistološkog stadijuma bolesti, tumor, nodus, metastaza (TNM) stadijuma bolesti, i primenjene hirurške terapije bolesti. Metode. Retrospektivnom studijom bilo je obuhvaćeno 252 bolesnika, hirurški lečenih od odmaklih karcinoma glave i vrata, sa periodom praćenja od pet godina. Bolesnici uključeni u studiju primarno su lečeni hirurški, sa sprovođenjem postoperativne radio- i hemioterapije, u zavisnosti od lokalne i regionalne proširenosti bolesti, intraoperativnog nalaza i granica linija resekcija. Petogodišnje ukupno preživljavanje i preživljavanje bez znakova bolesti računato je u zavisnosti od demografskih i kliničkih karakeristika bolesnika. Rezultati. Ukupno petogodišnje preživljavanje bolesnika sa odmaklim karcinomima larinksa je iznosilo 86,14%, a petogodišnje preživ­lja­vanje bez znakova bolesti 86,51%. Smanjeno preživljavanje bilo je značajno povezano sa starošću bolesnika, višim histološkim gradusom tumora i opsežnijim disekcijama vrata. Zaključak. Primarna totalna laringektomija rezultira dužim preživljavanjem u slučajevima transglotisnih T3 i T4a tumora larinksa. Pre donešenja odluke, bolesnici bi trebali biti informisani o mogućim većim rizicima od smrtnog ishoda povezanim sa izborom hirurške metode i drugih načina lečenja.

Reference

Ferlay J ,Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v 1.0,Cancer Incidence and Mor-tality Worldwide: IARC Cancer Base No. 11 (Internet). France, Lyon: International Agency for Research on Cancer; 2013

Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morri-son W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349(22): 2091–8.

Megwalu UC, Sikora AG. Survival outcomes in advanced lar-yngeal cancer. JAMA Otolaryngol Head Neck Surg 2014; 140(9): 855‒60.

Chen AY, Halpern M. Factors predictive of survival in ad-vanced laryngeal cancer. Arch Otolaryngol Head Neck Surg 2007; 133(12): 1270–6.

Dziegielewski PT, O'Connell DA, Klein M, Fung C, Singh P, Alex Mlynarek M, et al. Primary total laryngectomy versus organ preservation for T3/T4a laryngeal cancer: a population-based analysis of survival J Otolaryngol Head Neck Surg 2012; 41 Suppl 1: S56‒-64.

Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardizing survival ratios. Eur J Cancer 2004; 40(15): 2307‒16.

National Comprehensive Cancer Network. Head and neck cancers (Version 1.2017). Available from: http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. [accessed 2017September].

Sher DJ, Adelstein DJ, Bajaj GK, Brizel DM, Cohen EEW, Halt-hore A, et al .Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline. Pract Radiat Oncol 2017; 7(4): 246‒53.

Dyckhoff G, Plinkert PK, Ramroth HA. Change in the study evaluation paradigm reveals that larynx preservation compro-mises survival in T4 laryngeal cancer patients. BMC Cancer 2017; 17(1): 609.

Brandstorp-Boesen J, Sørum Falk R, Boysen M, Brøndbo K. Impact of stage, management and recurrence on survival rates in lar-yngeal cancer. PLoS One. 2017; 14;12(7): e0179371.

Saini AT, Genden EM, Megwalu UC.Sociodemographic dispari-ties in choice of therapy and survival in advanced laryngeal cancer. Am J Otolaryngol 2016; 37(2): 65‒9.

de Graeff A, de Leeuw JR, Ros WJ, Hordijk GJ, Blijham GH, Winnubst JA. Sociodemographic and quality of life as prognos-tic indicators in head and neck cancer. Eur J Cancer 2001; 37(3): 332–9.

Krejović B. The importance of surgery in treatment of malig-nant laryngeal tumors [dissertation]. Belgrade: Medical Faculty University in Belgrade; 1981. (Serbian)

Wolf GT, Fisher SG, Hong WK, Hillman R, Spaulding M, Laramore GE, et al. Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with ad-vanced laryngeal cancer. N Engl J Med 1991; 324(24): 1685–90.

Richard JM, Sancho-Garnier H, Pessey JJ, Luboinski B, Lefebvre JL, Dehesdin D, et al. Randomized trial of induction chemo-therapy in larynx carcinoma. Oral Oncol 1998; 34(3): 224–8.

Hoffman HT, Porter K, Karnell LH, Cooper JS, Weber RS, Langer CJ, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope 2006; 116(9 Pt 2 Suppl 111): 1‒13.

Cosetti M, Yu GP, Schantz SP. Five-year survival rates and time trends of laryngeal cancer in the US population. Arch Oto-laryngol Head Neck Surg 2008; 134(4): 370‒9.

Francis E, Matar N, Khoueir N, Nassif C, Farah C, Haddad A. T4a laryngeal cancer survival: retrospective institutional analy-sis and systematic review. Laryngoscope 2014; 124(7): 1618‒23.

Olsen KD. Reexamining the treatment of advanced laryngeal cancer. Head Neck 2010; 32(1): 1–7.

Djordjević V, Milovanović J, Petrović Z, Dudvarski Z, Petrović B, Stanković P. Radical surgery of the malignant laryngeal tu-mors.Acta Chir Iugosl 2004; 51(1): 31‒5.

Stanković M, Milisavljević D, Stojanov D, Zivić M, Zivaljević S, Stanković I, et al, Influential factors, complications and survival rate of primary and salvage total laryngectomy for advanced laryngeal cancer. Coll Antropol 2012; 36(Suppl 2): 7‒12.

Ferlito A, Silver CE, Rinaldo A. Selective neck dissection (IIA, III): a rational replacement for complete functional neck dis-section in patients with N0 supraglottic and glottic squamous carcinoma. Laryngoscope 2008; 118(4): 676–9.

Suárez C, Rodrigo JP, Robbins KT, Paleri V, Silver CE, Rinaldo A, et al.Superselective neck dissection: rationale, indications, and results. Eur Arch Otorhinolaryngol 2013; 270(11): 2815‒21.

Andersen PE, Warren F, Spiro J, Burningham A, Wong R, Wax MK, Shah JP, et al. Results of selective neck dissection in management of the node-positive neck. Arch Otolaryngol Head Neck Surg 2002; 128(10): 1180‒4.

Objavljeno
2021/03/04
Broj časopisa
Vol. 77 Br. 9 (2020): Vojnosanit pregl
Rubrika
Originalni članak